MESO-Rx
Anabolic Steroids
Then why are people so willing to pay such a huge tax to get aromasin instead of using the cheaper and more in supply adex? I don't get what the infatuation with aromasin is. The point of the AI is one thing, to control your estrogen, why not what's the cheapest and most readily available product that works? what am I missing here? I have never even considered using anything other than adex, it works great, I take my 0.5mg every day and i feel great...
^^this, also if I remember correctly, the half-life of Aromasin is just under 12 hours. This could play a factor in bloat if there are significant hormonal changes taking place daily that aren't being taken in to account
I started on adex because my urologist prescribes it to me. I asked him about the other popular AI's and he laughed saying people are always trying to reinvent the wheel, and to stick with adex as it works, and my insurance will easily cover it. It costs me about 3 bucks for 15mg's, can't really complain.
Man, and they still haven't changed it on the Arimidex website copyrighted this year:Here is the study for anyone wishing to read it
Journal home > Archive > Regular Articles > Abstract
Regular Article
British Journal of Cancer (2001) 85, 317–324. doi:10.1054/bjoc.2001.1925http://www.bjcancer.com/ (www.bjcancer.com)
Published online 31 July 2001
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
The ATAC Trialists' Group1,*
Topof page
Abstract
The ATAC trial evaluates in a randomized, double-blind design, Arimidex™ (anastrozole) alone or in combination with tamoxifen, relative to tamoxifen alone as 5-year adjuvant treatment in postmenopausal women with early breast cancer. Patients included in the pharmacokinetic (PK) sub-protocol had been in ATAC for ≥3 months, taking their medication in the morning and were 100% compliant for the preceding 14 days. Blood samples were collected 24 ± 4h after last dose. Trough (Cmin) plasma concentrations of anastrozole, tamoxifen and desmethyltamoxifen (DMT) were measured by validated methods. The PK results were based on a total of 347 patients (131 anastrozole (1mg o.d.), 111 tamoxifen (20mg o.d.), 105 anastrozole and tamoxifen (1 and 20mg o.d. respectively)). The geometric mean steady-state trough plasma concentrations of tamoxifen and DMT were statistically equivalent in patients receiving tamoxifen alone or in combination with anastrozole: geometric mean tamoxifen = 94.8ng ml–1and 95.3ng ml–1in tamoxifen alone and combination groups, respectively; geometric mean DMT = 265.1 and 277.6ng ml−1in the tamoxifen and anastrozole and tamoxifen groups, respectively. The geometric mean anastrozole levels were 27% lower (90% Cl 20–33%; P < 0.001) in the presence of tamoxifen than with anastrozole alone. Baseline plasma oestradiol levels were not obtained in the PK sub-protocol, however, such information was available from a similar ATAC sub-protocol, which evaluated bone mineral density. Mean oestradiol levels were 21.3, 19.3, and 21.6pmol l−1prior to treatment and 3.7, 20.9 and 3.6pmol l−1after 3 months in the anastrozole, tamoxifen, and combination groups, respectively (n= 167). On-treatment values were below the detection limit (3pmol l−1) in 43.6 and 38.5% of the anastrozole alone and anastrozole in combination with tamoxifen groups, respectively. As a result of (a) the lack of effect of anastrozole on tamoxifen and DMT levels and (b) the observed fall in blood anastrozole levels having no significant effect on oestradiol suppression by anastrozole, we conclude that the observed reduction in anastrozole levels by tamoxifen is unlikely to be of clinical significance when anastrozole and tamoxifen are administered together. © 2001 Cancer Research Campaign
